ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Viatris and Yuhan side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

ViatrisYuhan
studies on the registry778174
open to participants now935
phase 3 studies under way65
reach primary completion within a year810
programswith a study of their own in two years653

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseViatrisYuhan
Phase 100%

Yuhan: 45 of its 53 programs at phase 1

  1. AD-1161phase 1
  2. AD-116Aphase 1
  3. AD-118phase 1
  4. AD-230phase 1
  5. PA-111phase 1

and 40 more — sign in to see them all

85%
Phase 2

Viatris: 1 of its 6 programs at phase 2

  1. MR-130A-01phase 2
17%

Yuhan: 3 of its 53 programs at phase 2

  1. AD-211phase 2
  2. lesigerceptphase 2
  3. YH32364phase 2
6%
Phase 3

Viatris: 2 of its 6 programs at phase 3

  1. cenerimodphase 3
  2. selatogrelphase 3
33%

Yuhan: 5 of its 53 programs at phase 3

  1. AD-227Bphase 3
  2. AD-233Aphase 3
  3. AD-233Bphase 3
  4. AD-2282phase 3
  5. YHP2401phase 3
9%
Approved, new studies

Viatris: 3 of its 6 programs at approved, new studies

  1. Gabapentinapproved, new study
  2. Alprazolamapproved, new study
  3. Treatment with 137 µg azelastine hydrochloride and 50 μg of fluticasone propionateapproved, new study
50%
00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Viatris4 readouts · 3 phase 3

Viatris, Nov ’26: 1 program whose next study reaches primary completion

  1. MR-130A-01phase 2 · Nov 30 · NCT07365904

Viatris, Dec ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. cenerimodphase 3 · Dec 31 · NCT05672576

Viatris, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. Gabapentinapproved, new study · Jan 31 · NCT07813026
·····

Viatris, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. selatogrelphase 3 · Jul 0 · NCT04957719
···
Yuhan10 readouts · 0 phase 3

Yuhan, Nov ’26: 3 programs whose next study reaches primary completion

  1. AD-234phase 1 · Nov 0 · NCT07717775
  2. AD-2341phase 1 · Nov 0 · NCT07717775
  3. AD-2342phase 1 · Nov 0 · NCT07717775
·

Yuhan, Jan ’27: 2 programs whose next study reaches primary completion

  1. YHP2508Bphase 1 · Jan 26 · NCT07912840
  2. YHR2602phase 1 · Jan 26 · NCT07912840

Yuhan, Feb ’27: 2 programs whose next study reaches primary completion

  1. YHP2508Aphase 1 · Feb 2 · NCT07912827
  2. YHR2601phase 1 · Feb 2 · NCT07912827

Yuhan, Mar ’27: 1 program whose next study reaches primary completion

  1. AD-211phase 2 · Mar 0 · NCT07550231
··

Yuhan, Jun ’27: 2 programs whose next study reaches primary completion

  1. YH32364phase 2 · Jun 0 · NCT06975410
  2. lesigerceptphase 2 · Jun 19 · NCT07415551
····
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Viatris

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Yuhan

New programs 6

  • YHP2508Aphase 1 · first study · Oct 28
  • YHP2508Bphase 1 · first study · Oct 28
  • YHR2601phase 1 · first study · Oct 28
  • YHR2602phase 1 · first study · Oct 28
  • AD-233Aphase 3 · first study · Sep 7 · Diabetes Mellitus, Type 2
  • AD-233Bphase 3 · first study · Sep 7 · Diabetes Mellitus, Type 2

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

No condition where two of them both have programs.

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Viatris 4 of 6 · Yuhan 1 of 53 programs (5 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.